In Brief: St. Jude
This article was originally published in The Gray Sheet
Executive Summary
St. Jude: St. Paul, Minnesota-based firm organizing tachycardia personnel and resources under the leadership of Mark Kroll, PhD, former VP Research and Product Planning at Minneapolis-based Angeion Corporation, who is appointed VP of the new St. Jude tachycardia division. St. Jude plans to form an advanced tachycardia research team in Minnesota to further its platform tachycardia technology; the firm holds rights to the technology through ongoing cross-patent and technology licensing agreements with Angeion. The firm also holds a worldwide distribution agreement to sell Angeion's Sentinel 2000 and 2001 implantable cardiac defibrillator models under a Pacesetter tradename. St. Jude expects the first implant of the ICD to occur in early 1996, according to an Oct. 31 release. In a separate release, Angeion reports that it received FDA approval to begin its own clinical trials in the U.S. for the Sentinel 2000 defibrillation system...